Import Your Data

FAQ

More QuickView FAQs

QuickView

0
Meta-
Analysis

Bookmark Forward

QuickView for Fludarabine (compound)

Summary
General Info

PubChem

PubChem Compound 657237

PubChem Compound 657237

Name:	fludarabine
PubChem Compound ID:	657237
Molecular formula:	C₁₀H₁₂FN₅O₄
Molecular weight:	285.232 g/mol
Synonyms:	9-beta-D-Arabinofuranosyl-2-fluoroadenine; Fludara; MLS000028687; 21679-14-1; 2-Fluoro-9-beta-D-arabinofuranosyladenine; NSC 118218H; NSC-118218; Fludarabine; 9H-Purin-6-amine, 9-beta-D-arabinofuranosyl-2-fluoro- (9CI); EINECS 244-525-5. show more » 9-beta-D-Arabinofuranosyl-2-fluoroadenine; Fludara; MLS000028687; 21679-14-1; 2-Fluoro-9-beta-D-arabinofuranosyladenine; NSC 118218H; NSC-118218; Fludarabine; 9H-Purin-6-amine, 9-beta-D-arabinofuranosyl-2-fluoro- (9CI); EINECS 244-525-5; NSC 118218; Fludarabine phosphate; SMR000058874; 9-beta-D-Arabinosyl-2-fluoroadenine; Fludarabina [Spanish]; CCRIS 3382; F-Ara-A; HSDB 6964; Fludarabinum [Latin]; 2-Fluoro Ara-A; 2-F-ara-A; Adenine, 9-beta-D-arabinofuranosyl-2-fluoro- show less «

DrugBank

Identification

Name:	fludarabine
Name (isomeric):	DB01073
Drug Type:	small molecule
Synonyms:	Fludarabine 5'-monophosphate; Fludarabine phosphate; FAMP; Fludarabine monophosphate
Brand:	Fludura, Fludara
Category:	Antimetabolites, Antimetabolites, Antineoplastic, Antineoplastic Agents, Immunosuppressive Agents
CAS number:	75607-67-9

Pharmacology

Indication:	For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen
Pharmacology:	Fludarabine is a chemotherapy drug used in the treatment of chronic lymphocytic leukemia. It acts at DNA polymerase alpha, ribonucleotide reductase and DNA primase, results in the inhibition of DNA synthesis, and destroys the cancer cells.
Mechanism of Action:	Fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite appears to act by inhibiting DNA polymerase alpha, ribonucleotide reductase and DNA primase, thus inhibiting DNA synthesis. The mechanism of action of this ... show more » Fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite appears to act by inhibiting DNA polymerase alpha, ribonucleotide reductase and DNA primase, thus inhibiting DNA synthesis. The mechanism of action of this antimetabolite is not completely characterized and may be multi-faceted. show less «
Absorption:	Bioavailability is 55% following oral administration.
Protein binding:	19-29%
Half Life:	20 hours
Clearance:	117-145 mL/min [patients with B-cell CLL receiving IV administration of a single dose of 40 mg/m2]
Affected organisms:	Humans and other mammals

Interactions

Food interaction:

Food slightly increases product bioavailability.

Take without regard to meals.

Drug interaction:

Pentostatin	Unacceptable pulmonary toxicity
Trastuzumab	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Dipyridamole	Dipyridamole may decrease the effect of fludarabine.

Targets

Ribonucleoside-diphosphate reductase large subunit

DNA polymerase alpha catalytic subunit

Deoxycytidine kinase

Transporters

Equilibrative nucleoside transporter 1